Key result
Systemic lupus erythematosus patients have an increased prevalence of metabolic syndrome and insulin resistance, which may drive an increased risk of cardiovascular disease.
Identifying metabolic syndrome in SLE patients is important for targeting lifestyle interventions and medication adjustments to reduce future cardiovascular disease risk.
May prompt metabolic screening in SLE; confirms associations with insulin resistance but leaves intervention effects on CVD open.
Metabolic syndrome (MetS) is a recently defined clustering of cardiovascular risk factors associated with insulin resistance and an increased risk of future type II diabetes mellitus and cardiovascular disease (CVD). Systemic lupus erythematosus (SLE) patients have an increased prevalence of MetS and an increased prevalence of insulin resistance. Chronic inflammation may predispose to these complications in SLE and there is also evidence that corticosteroid therapy also contributes, although this finding has not been as consistent as would be predicted from the known metabolic effects of corticosteroids. MetS may represent a good model in which to begin to understand how SLE drives an increased risk of CVD. For now, the utility of identifying MetS in patients is to identify a subset in which more focused lifestyle interventions should be targeted and in whom medication review and adjustment (especially corticosteroid doses) should be considered to help modify future CVD risk.
No takes yet. Share an insight, caveat, or question.
Parker et al. (2013) conducted a review in Systemic lupus erythematosus (SLE) and Metabolic syndrome (MetS). Metabolic syndrome and corticosteroid therapy was evaluated. Systemic lupus erythematosus patients have an increased prevalence of metabolic syndrome and insulin resistance, which may drive an increased risk of cardiovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: